Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial. Jun 4, 2019
Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy for CAR-T Feb 20, 2019
Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Webcast Jul 10, 2018
![Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.](https://d1io3yog0oux5.cloudfront.net/_d6fff4282cea7e5c07812f8ed03c4212/actiniumpharma/db/206/925/pdf_thumbnail.jpg "Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.")
